Aran Anandakumar, former Investment Analyst at Barclay Pearce Capital, shares with us his insights into the 2021 Covid-19 vaccine situation in Australia.
Australia is one of the world's success stories in its fight against COVID-19, but concern is growing over the delays with the vaccination rollout and the health issues associated with it.
So far 1.6 million vaccine doses have been administered nationwide, well short of the 4 million dose goal originally set. The TGA received reports of ~30 deaths in 40,000 elderly individuals in Norway who were dosed with the Pfizer vaccine.
Then in March, there were multiple reports linking the AstraZeneca vaccine and a syndrome called thrombosis in combination with thrombocytopenia, which is an extremely rare blood clotting syndrome that can cause long-term disability and even death.
Learn more
---------------------------------------------------------------------------------------------------
Barclay Pearce Capital Pty Ltd is a Corporate Authorised Representative (Authorisation Number: 1277964) of Barclay Pearce Capital Management Pty Ltd, the holder of an Australian Financial Services Licence (Number: 503261).
This podcast is for information purposes only and should not be construed as an offer or solicitation or recommendation to buy or sell financial products. The information contained in this podcast is directed and available to residents of Australia only. The distribution of information to persons outside this criteria may be restricted by law and persons who come into possession of it should seek advice and observe any such restriction.
The information provided in this podcast is general in nature only and does not constitute personal advice. The information has been prepared without taking into account you or your company’s objectives, financial situation or needs. Before acting on any information in this podcast you should consider the appropriateness of the information having regard to your objectives, financial situation and needs. You should seek independent financial advice and read the relevant disclosure statements or other offer documents prior to making an investment decision about a financial product.